A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users

Summary

The purposes of this study are 1) to determine if the administration of different low doses of oral CBD (20 mg, 50 mg, 100 mg and 200 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively explore whether low dose of oral CBD is associated with effects that are not detected with the available research tools.

Timeline

Start

2022-07-22

Primary completion

2023-11-14

Completion

2023-11-14

Outcome

Met primary endpoint

paper Two hundred milligrams of synthetic CBD dose produced an average 12.8% [95% CI = 3.8% to 21.8%] higher peak pleasant drug effect score compared to placebo PMID 42454450 ↗

paper No other dose of CBD showed a significant effect for the primary outcome versus placebo. PMID 42454450 ↗

Publications

• Chester LA, Hebert FO, Lachance-Touchette P, Mahroug A, Abboud A, McCrea TP, Mansour S, Marsan S, Jutras-Aswad D. Acute behavioural effects of low-dose cannabidiol: A randomised crossover trial in healthy volunteers. J Psychopharmacol. 2026 Jul 15:2698811261464527. doi: 10.1177/02698811261464527. Online ahead of print.
• Abboud A, Chester LA, Hebert FO, Jutras-Aswad D. Sex-specific association between low oral doses of cannabidiol (CBD) and plasma concentration of anandamide (AEA), N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) in healthy occasional cannabis users. J Cannabis Res. 2026 Jan 9;8(1):20. doi: 10.1186/s42238-025-00356-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	20 mg	Oral
Subject	Cannabidiol	Other / unclassified	50 mg	Oral
Subject	Cannabidiol	Other / unclassified	100 mg	Oral
Subject	Cannabidiol	Other / unclassified	200 mg	Oral

Indications